Cell/Gene Tx channel feed

Fate's close­ly watched stem cell-de­rived NK pro­gram rais­es red flag over dura­bil­i­ty of re­sponse

4 years ago
R&D

Search­ing for ways to boost CAR-T re­sponse, Penn re­searchers find a ca­pa­ble wing­man in BET in­hibitors

4 years ago
Discovery

FDA lifts clin­i­cal hold on Rock­et's gene ther­a­py for heart fail­ure af­ter 3-month de­lay

4 years ago
FDA+

Longeveron's cell ther­a­py flops ear­ly walk test study as ex­ecs tout flim­sy sup­port­ing da­ta

4 years ago

Mer­ck part­ner Arti­va blue­prints San Diego R&D, man­u­fac­tur­ing site to take NK cell op­er­a­tion to the next lev­el

4 years ago
Manufacturing

Bi­o­Life So­lu­tions sets up shop in In­di­anapo­lis, adding a slate of new cell and gene ther­a­py tools to its belt

4 years ago
Deals
Manufacturing

Blue­bird forced to halt tri­als af­ter a can­cer-like case, pulls gene ther­a­pies from Eu­rope fol­low­ing pric­ing back­lash — shares slammed

4 years ago
R&D
FDA+

FDA lifts year-plus hold on No­var­tis' Zol­gens­ma, set­ting the stage for new PhI­II

4 years ago
FDA+

Ad­verum faces murky fu­ture af­ter re­view turns up deep­er safe­ty is­sues for gene ther­a­py

4 years ago
R&D

Af­ter slic­ing and dic­ing TCRs for 8 years, Swedish biotech re­loads to an­gle for a spot in crowd­ed cell ther­a­py space

4 years ago
Financing

Sean Park­er-backed cell ther­a­py start­up Ar­se­nal­Bio plucks Mer­ck VP as new CSO

4 years ago
People

Flex­ing its new­found wealth, BioN­Tech snaps up a TCR plat­form and man­u­fac­tur­ing site as Gilead ex­its

4 years ago
Deals
Manufacturing

Celu­lar­i­ty emerges from SPAC merg­er dou­bled down on cell ther­a­pies as Bob Hariri down­grades ill-fat­ed Covid-19 pro­gram

4 years ago
Deals

As its next big bet, Sana inks long-term lease for man­u­fac­tur­ing site for next-gen cell ther­a­pies

4 years ago
Manufacturing

EX­CLU­SIVE: Shape Ther­a­peu­tics rais­es $112M in bid to make RNA edit­ing — and a whole lot else — a re­al­i­ty

4 years ago
Financing

A stealthy start­up is lever­ag­ing nat­ur­al killer cells with 'mem­o­ry-like' abil­i­ties to go af­ter blood can­cer and be­yond

4 years ago
Financing

Nkar­ta signs its name to an am­bi­tious fu­ture with man­u­fac­tur­ing hub for not one but mul­ti­ple mar­ket­ed drugs

4 years ago
Manufacturing

David Liu takes the wraps off $315M launch round for Prime Med­i­cine and new CRISPR tech that gave Bob Nelsen a 'holy crap' mo­ment

4 years ago
Financing
Startups

Switch­ing fo­cus in the brain, re­searchers her­ald a pos­si­ble gene ther­a­py break­through in treat­ing an ul­tra-rare dis­ease

4 years ago
R&D

With Lenti­Glo­bin cleared by FDA, blue­bird lifts EU mar­ket­ing hold on gene ther­a­py us­ing the same de­liv­ery mech­a­nism

4 years ago

Apel­lis, Beam team up to test base edit­ing against the broad field of com­ple­ment dis­or­ders

4 years ago
Deals

Gen­Sight's gene ther­a­py mys­tery con­tin­ues, as pa­tients im­prove in an­oth­er failed tri­al

4 years ago
R&D

Sanofi in­vests in the fu­ture of mR­NA with plan to pump bil­lions of dol­lars in­to next-gen cell ther­a­py busi­ness

4 years ago
R&D
Manufacturing

Gilead­'s Kite earns sec­ond-line win for CAR-T Yescar­ta, set­ting up a bat­tle over ear­li­er blood can­cer pa­tients

4 years ago
R&D
Pharma
First page Previous page 37383940414243 Next page Last page
A service from the Financial Times